
Drugs & Supplements
Prescription drugs, over-the counter medications, and supplements

Popular Drugs & Supplements
- Vitamin D3 (Cholecalciferol (Vitamin D3))
- Valtrex (Valacyclovir)
- Metronidazole (Flagyl)
- Doxycycline (Vibramycin)
- Methylcobalamin (Vitamin B12 Methylcobalamin)
- Macrobid (Nitrofurantoin)
- Azithromycin (Zithromax)
- Vitamin C Plus Zinc (Multivitamins And Minerals)
- Fosamax (Alendronate)
- Crestor (Rosuvastatin)
- Tylenol (Acetaminophen (Injection))
- Naproxen (Aleve)
- Diclofenac (Voltaren)
- Benadryl (Diphenhydramine)
- Rocephin (Ceftriaxone (Injection))
- Prevagen (Oral)
- Celebrex (Celecoxib)
- Methylprednisolone (Medrol)
- Folic Acid (FA-8)
- Quetiapine (Seroquel)
- Paxlovid (Nirmatrelvir and Ritonavir)
- Potassium Chloride (Kato)
- Ozempic (Subcutaneous)
- Lexapro (Escitalopram)
- Psyllium (Metamucil)
- Magnesium Oxide (Mag-Ox 400)
- Calcium And Vitamin D Combination (Calcium 500+D)
- Benzonatate (Tessalon Perles)
- Bactrim (Sulfamethoxazole and Trimethoprim Oral/Injection)
- Zoloft (Sertraline)
Latest FDA News
Ongoing | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
By FDA
Reviewed:
Verified Clinical Benefit | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
By FDA
Reviewed:
Electronic Registration and Listing Compliance Program
Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL).
By FDA
Reviewed:
Liver Toxicity Knowledge Base (LTKB)
Overview of the Liver Toxicity Knowledge Base project at the FDA's National Center for Toxicological Research to study drug-induced liver injury (DILI) with links to the LTKB Dataset, DILIrank and DILIst Datasets, references, and contact information for questions, suggestions, or technical support.
By FDA
Reviewed:
Patient Engagement Collaborative
The Patient Engagement Collaborative (PEC) is an advancement in the FDA’s efforts to strengthen its relationship with patient communities and is being coordinated by the FDA’s Office of Patient Affairs in the Office of Clinical Policy and Programs (OCPP).
By FDA
Reviewed:
Medical Disclaimer
Drugs A-Z provides drug information from Everyday Health and our partners, as well as ratings from our members, all in one place. Cerner Multum™ provides the data within some of the Overview, Uses, Warnings, Side Effects, Pregnancy, Interactions, Dosage, Overdose, and Images sections. The information within all other sections is proprietary to Everyday Health.